Blog
This Fund Manager Just Sold Nearly $12 Million in Municipal Bonds. Here's Why.
On May 15, 2026, 1607 Capital Partners reported selling 1,279,272 shares of Nuveen Municipal Value Fund (NYSE:NUV), an estimated $11.68 million trade based on quarterly average pricing. The fund
This Fintech Stock Lagged the Market as One Fund Dumped a $4.6 Million Stake
On May 15, 2026, 13D Management disclosed a full exit from WEX (NYSE:WEX), selling 29,350 shares in a trade estimated at $4.59 million based on quarterly average pricing.
According to a Securities
Here's Why Brady Corporation Soared 17% Today (Hint: Its AI Related)
Brady Corporation (NYSE: BRC) rose by almost 17% by 2 p.m today on the release of its stellar third quarter 2026 earnings report. Clearly, the company has excellent trading momentum because
The Bull and Bear Cases for Investing in SoundHound AI Stock
SoundHound AI (NASDAQ: SOUN) is a voice artificial intelligence (AI) company that has been a polarizing investment. It possesses some exciting growth opportunities in tech, and with a market cap of
The Sectors Quietly Winning While Investors Focus on Tech
Most investors remain hyperfocused on technology stocks and artificial intelligence (AI) stocks in particular -- understandably so. AI still promises to revolutionize the world in ways we've yet to
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
On May 15, 2026, ADAR1 Capital Management disclosed in an SEC filing that it bought 1,819,339 Denali Therapeutics shares, an estimated $36.20 million trade based on quarterly average pricing.
Should You Lock In Gains Before Summer or Let Your Winners Ride?
Over the past 12 months, the S&P 500 and Nasdaq have risen about 25% and 35%, respectively. Both indexes are hovering near record highs and trading at historically high valuations, even amid
Nvidia Stock Investors Just Got (More) Fantastic News from Wall Street
Nvidia (NASDAQ: NVDA) stock has rewarded shareholders since early 2023, racking up gains of 1,420% -- but it hasn't all been smooth sailing. The artificial intelligence (AI) chipmaker has tumbled
AI Isn't Just GPUs and CPUs: Here's the AI Trade No One Is Talking About
Much of the attention surrounding the AI infrastructure buildout is focused on GPUs and CPUs, and for good reason. But meanwhile, Micron (NASDAQ: MU), SanDisk (NASDAQ: SNDK), and other manufacturers
Why Poet Technologies Is Plummeting Today
Poet Technologies (NASDAQ: POET) stock is moving lower in Monday's trading. The company's share price was down 12.6% as of 2:05 p.m. ET. The S&P 500 was down 0.3% at the same point in the daily
This Nvidia-Backed Company Just Entered an $800 Billion Agentic AI Market. Does This Make the $14 Stock a No-Brainer Buy?
In the world of telecommunications, Nokia (NYSE: NOK) is undergoing a quiet, albeit noteworthy, transformation. The company that was once synonymous with mobile phones is pivoting beyond its more
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
On May 15, 2026, ADAR1 Capital Management disclosed a new position in Beam Therapeutics (NASDAQ:BEAM), acquiring 1,446,375 shares in an estimated $40.13 million trade based on quarterly average
NuScale Power Just Reported Earnings. Here's Why I'd Buy After the Numbers Dropped.
NuScale Power (NYSE: SMR) has huge growth potential. The nuclear company is chasing a multi-trillion-dollar opportunity that should persist for decades to come.
That opportunity is made possible
3 High-Yielding Dividend Stocks Trading at Dirt Cheap Valuations
Want to invest in a stock that's incredibly cheap, that offers a high yield, and whose payout is safe? I've got a list of three such stocks that meet that criteria, and that could make for
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
On May 15, 2026, ADAR1 Capital Management disclosed a buy of 829,963 shares of Crinetics Pharmaceuticals (NASDAQ:CRNX), an estimated $37.07 million trade based on quarterly average pricing.
This Fintech Stock Fell 17% Last Year. One Fund Just Fully Exited a $4 Million Stake
13D Management sold out its entire position in Bill.com (NYSE:BILL) during the first quarter, according to a May 15, 2026, SEC filing. The estimated transaction value was $4.03 million, based on
This Beaten-Down Tech Stock Presents a Generational Buying Opportunity
"Magnificent Seven" stocks have a long history of beating the S&P 500, but Meta Platforms (NASDAQ: META), one of the seven, has been a recent laggard. It's down by 4% over the past year, while the
Why This Fund Made a $5 Million Bet on Acadia Healthcare Despite a Flat Stock
On May 15, 2026, 13D Management disclosed a new position in Acadia Healthcare (NASDAQ:ACHC), acquiring 294,000 shares in a trade estimated at $5.32 million based on quarterly average pricing.
This Wealth Manager Just Bet $5.8 Million on BlackRock's Active Country Rotation ETF
On May 15, 2026, Barnes Wealth Management Group disclosed a new position in BlackRock ETF Trust - iShares International Country Rotation Active ETF (NASDAQ:CORO), acquiring 180,394 shares for an
If You Do This With Your Inherited IRA, You're Probably Costing Yourself Big Time
You probably have a lot of ideas about what you'd like to do with your inherited individual retirement account (IRA), and you're free to do whatever you want with the money. But there are still a
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
On May 15, 2026, Octagon Capital Advisors disclosed a new stake in Xenon Pharmaceuticals (NASDAQ:XENE), acquiring 490,000 shares in a transaction estimated at $22.58 million based on quarterly
3 Stocks That Have Turned $15,000 Into $4 Million in 20 Years
A buy-and-hold strategy can generate life-changing returns for investors, and the stocks listed below are prime examples of that. While there can be risks with investing in companies in their early
Here's Why Ryanair Stock Flew Higher Today
Shares in Ireland's ultra-low-cost carrier Ryanair Holdings (NASDAQ: RYAAY) popped higher by 8.4% in early morning trading as the market digested an excellent set of fourth-quarter earnings. The
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Octagon Capital Advisors cut its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 470,000 shares, an estimated $27.22 million trade based on quarterly average pricing, according to a May 15, 2026 SEC
Prediction: This Beaten-Down Tech Stock Will Outperform the S&P 500 by 2027
Some stock drops present meaningful long-term buying opportunities for patient investors who can ignore the noise. Reddit (NYSE: RDDT) looks like one of those growth stocks. It's down by more than